Opus Point Partners Management as of Sept. 30, 2016
Portfolio Holdings for Opus Point Partners Management
Opus Point Partners Management holds 48 positions in its portfolio as reported in the September 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| iShares Russell 2000 Index (IWM) | 24.4 | $44M | 350k | 124.21 | |
| SPDR S&P Biotech (XBI) | 20.8 | $37M | 560k | 66.29 | |
| iShares NASDAQ Biotechnology Index (IBB) | 4.1 | $7.2M | 25k | 289.44 | |
| Bristol Myers Squibb (BMY) | 3.6 | $6.5M | 121k | 53.91 | |
| Merck & Co (MRK) | 2.9 | $5.2M | 84k | 62.41 | |
| Proshares Tr pshs ult nasb (BIB) | 2.3 | $4.1M | 85k | 48.46 | |
| AstraZeneca (AZN) | 2.2 | $3.9M | 120k | 32.86 | |
| Alkermes (ALKS) | 2.1 | $3.8M | 82k | 47.03 | |
| Pfizer (PFE) | 2.1 | $3.8M | 112k | 33.87 | |
| Seattle Genetics | 2.1 | $3.7M | 68k | 54.01 | |
| Biogen Idec (BIIB) | 1.9 | $3.4M | 11k | 313.06 | |
| Illumina (ILMN) | 1.9 | $3.3M | 18k | 181.68 | |
| Incyte Corporation (INCY) | 1.8 | $3.3M | 35k | 94.29 | |
| Amgen (AMGN) | 1.7 | $3.1M | 18k | 166.79 | |
| Alnylam Pharmaceuticals (ALNY) | 1.7 | $3.1M | 45k | 67.77 | |
| Qiagen | 1.7 | $3.0M | 111k | 27.44 | |
| Nektar Therapeutics (NKTR) | 1.7 | $3.0M | 177k | 17.18 | |
| Regeneron Pharmaceuticals (REGN) | 1.7 | $3.0M | 7.5k | 402.02 | |
| Mettler-Toledo International (MTD) | 1.7 | $3.0M | 7.2k | 419.87 | |
| Alexion Pharmaceuticals | 1.7 | $3.0M | 25k | 122.54 | |
| Agios Pharmaceuticals (AGIO) | 1.6 | $2.9M | 55k | 52.82 | |
| BioMarin Pharmaceutical (BMRN) | 1.6 | $2.8M | 31k | 92.53 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 1.6 | $2.8M | 32k | 87.21 | |
| Celgene Corporation | 1.6 | $2.8M | 27k | 104.55 | |
| Ionis Pharmaceuticals (IONS) | 1.6 | $2.8M | 76k | 36.64 | |
| GlaxoSmithKline | 1.4 | $2.6M | 60k | 43.13 | |
| Pacira Pharmaceuticals (PCRX) | 1.0 | $1.7M | 50k | 34.22 | |
| Medicines Company | 0.6 | $1.1M | 28k | 37.75 | |
| Paratek Pharmaceuticals | 0.6 | $1.0M | 80k | 13.01 | |
| Adamas Pharmaceuticals | 0.6 | $985k | 60k | 16.42 | |
| New Senior Inv Grp | 0.5 | $966k | 84k | 11.54 | |
| Contrafect | 0.4 | $744k | 300k | 2.48 | |
| Direxion Shs Etf Tr sp biotch bl | 0.4 | $714k | 15k | 48.77 | |
| Proshs Ultrashrt S&p500 Prosha etf | 0.4 | $656k | 40k | 16.40 | |
| Portola Pharmaceuticals | 0.3 | $568k | 25k | 22.72 | |
| Ultragenyx Pharmaceutical (RARE) | 0.3 | $502k | 7.1k | 70.96 | |
| Cepheid | 0.2 | $315k | 6.0k | 52.63 | |
| Ophthotech | 0.2 | $311k | 6.7k | 46.10 | |
| Neurocrine Biosciences (NBIX) | 0.1 | $206k | 4.1k | 50.64 | |
| United Therapeutics Corporation (UTHR) | 0.1 | $209k | 1.8k | 118.21 | |
| Intercept Pharmaceuticals In | 0.1 | $215k | 1.3k | 164.62 | |
| Quintiles Transnatio Hldgs I | 0.1 | $221k | 2.7k | 80.95 | |
| Juno Therapeutics | 0.1 | $208k | 6.9k | 30.07 | |
| Axovant Sciences | 0.1 | $208k | 15k | 14.01 | |
| Grifols S A Sponsored Adr R (GRFS) | 0.1 | $189k | 12k | 15.95 | |
| Lion Biotechnologies | 0.1 | $194k | 24k | 8.22 | |
| Seres Therapeutics (MCRB) | 0.1 | $172k | 14k | 12.29 | |
| Novavax | 0.0 | $54k | 26k | 2.09 |
